...
首页> 外文期刊>Biology and Medicine >Study of Molecular Mechanisms of PDLIM4/RIL in Promotion of the Development of Breast Cancer
【24h】

Study of Molecular Mechanisms of PDLIM4/RIL in Promotion of the Development of Breast Cancer

机译:PDLIM4 / RIL促进乳腺癌发生的分子机制研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

PDLIM4 (RIL) gene is often subjected to epigenetic suppression in malignant tumors of various organs. At the same time, reasons of this suppression are not fully understood, and the only effect of the proposed mechanism of PDLIM4 impact on malignant transformation of epithelial cells is partially refuted by new experimental data. In order to determine a range of targets, which can be affected by changes in the level of PDLIM4 expression, a model system based on the breast cancer cell line MDA-MB-231 was created and characteristics were given to the model. The model had artificially suppressed PDLIM4 expression by introduced shRNA expression promoter. Comparative transcriptome sequencing before and after the suppression of PDLIM4 revealed a number of genes whose expression levels correlated with a change in PDLIM4 expression. Most of these genes related to the MAPK signal pathway. Based on the data obtained, the most likely candidate genes were offered, which may play the role of the end effectors that stimulate malignant transformation after PDLIM4 suppression. *Corresponding author: Frolova EI, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 16/10 Ulitsa Miklukho- Maklaya, GSP-7, Moscow 117997, Russian Federation; E-mail: eifr@ibch.ru Received: Jan 11, 2016; Accepted: Mar 14, 2016; Published: Apr 13, 2016 Citation: Kravchenko DS, Lezhnin YN, Kravchenko JE, Chumakov SP, Frolova EI (2016) Study of Molecular Mechanisms of PDLIM4/RIL in Promotion of the Development of Breast Cancer. Biol Med (Aligarh) 8(2): BM-175-16, 6 pages. Copyright: . 2016 Kravchenko et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
机译:PDLIM4(RIL)基因经常在各种器官的恶性肿瘤中受到表观遗传抑制。同时,尚不完全了解这种抑制的原因,并且新的实验数据部分驳斥了所提出的PDLIM4机制对上皮细胞恶性转化的影响。为了确定可能受PDLIM4表达水平变化影响的靶标范围,建立了基于乳腺癌细胞系MDA-MB-231的模型系统,并赋予了模型特征。该模型通过导入的shRNA表达启动子人工抑制了PDLIM4表达。在抑制PDLIM4之前和之后的比较转录组测序显示了许多基因,其表达水平与PDLIM4表达的变化相关。这些基因大多数与MAPK信号通路有关。根据获得的数据,提供了最可能的候选基因,这些基因可能发挥末端效应子的作用,在PDLIM4抑制后刺激恶性转化。 *通讯作者:俄罗斯科学研究院Shemyakin-Ovchinnikov生物有机化学研究所的Frolova EI,俄罗斯联邦莫斯科117997,GSP-7,Ulitsa Miklukho- Maklaya,16/10;电子邮件:eifr@ibch.ru收到:2016年1月11日;接受:2016年3月14日;发布时间:2016年4月13日引文:Kravchenko DS,Lezhnin YN,Kravchenko JE,Chumakov SP,Frolova EI(2016)PDLIM4 / RIL促进乳腺癌发展的分子机制研究。 Biol Med(Aligarh)8(2):BM-175-16,6页。版权:。 2016年Kravchenko等。这是根据知识共享署名许可协议条款分发的开放获取文章,该文章允许在任何媒介中无限制地使用,分发和复制,但要注明原始作者和出处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号